Compare ABLV & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABLV | PRPO |
|---|---|---|
| Founded | 2015 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 32.4M |
| IPO Year | N/A | N/A |
| Metric | ABLV | PRPO |
|---|---|---|
| Price | $0.74 | $24.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 19.6K | 8.7K |
| Earning Date | 09-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $114,319,869.00 | $22,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.66 | ★ N/A |
| Revenue Growth | N/A | ★ 30.95 |
| 52 Week Low | $0.59 | $3.90 |
| 52 Week High | $1.77 | $28.50 |
| Indicator | ABLV | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 52.79 |
| Support Level | $0.65 | $23.77 |
| Resistance Level | $0.77 | $25.64 |
| Average True Range (ATR) | 0.07 | 1.47 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 64.29 | 28.79 |
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.